Prostate Cancer Market19 Oct 2023 19:25
Quote: “Currently, metastatic prostate cancer is associated with substantial annual healthcare costs, which have increased over time as new oral therapies for the treatment of metastatic prostate cancer have been approved. USA population-level incidence of metastatic prostate cancer decreased after prostate cancer screening with PSA testing was widely adopted.
Future generations will be among the first to witness more affordable, accessible, and diagnostic-associated treatment approaches for prostate cancer as the incidence of the disease increases in the future. In an attempt to address the challenges faced by prostate cancer research organizations & societies, governments are investing in numerous initiatives that are meant to raise awareness about the disease, thereby assisting them in developing effective medications.”
So first observation : ‘ USA population-level incidence of metastatic prostate cancer decreased after prostate cancer screening with PSA testing was widely adopted.’
- Yes imagine the impact PSE will have then if the relatively ineffective PSA had an effect.
Second observation: ‘ Future generations will be among the first to witness more affordable, accessible, and diagnostic-associated treatment approaches for prostate cancer’
- Not future generations, THIS generation. Now! Because of the cost saving impact of PSE.